ReadCube
Depends
Confidence: Medium
Buy if you run an R&D, pharma, or corporate-library team that shares and annotates papers daily.
New check
Comparison
ReadCube and EndNote both land on Depends.
Buy if you run an R&D, pharma, or corporate-library team that shares and annotates papers daily.
Buy it if your institution provides a site license or you run heavy systematic reviews in Microsoft Word.
| Compare | ||
|---|---|---|
| Verdict | Depends | Depends |
| Best for | Pharma and biotech R&D teams | Systematic review teams |
| Who it's not for | Solo researchers . free Zotero covers you | Students and solo researchers on a budget |
| Privacy | No known public vulnerabilities found in the sources reviewed.³ | Low-to-moderate risk: one reported XSS on (marked patched); a US VA advisory notes a product vulnerability. |
| Support quality | Help center exists; support claims unverified | No direct support-quality evidence found |
| Public sentiment | Users praise ReadCube's reading and annotation tools but wrestle with citations and were unsettled by the Papers app relaunch.⁶ | Longtime users praise its Word integration and systematic-review muscle, while many academics on Reddit complain about bugs and recommend free Zotero instead. |
| Biggest gotcha | Group plans cap at 10 users per group; larger teams likely pushed to enterprise sales² | Standalone is $275 one-time; confirm whether future major versions cost extra16 |